This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
Summary of the STEPS trial which will be a twitter spaces discussion
This week, we will discuss the HIT trial- a large randomized study challenging one of the most reflexive responses in hospital medicine: see hyponatremia, fix the sodium. But what if correcting the number doesn’t change what actually matters?
La hiponatremia es uno de los trastornos electrolíticos más frecuentes en pacientes hospitalizados y se asocia de manera consistente con peores desenlaces. Su corrección mejora los valores, pero ¿realmente mejora los desenlaces clínicos ?
Revisa el resumen visual por Brian Rifkin y el nuevo formato de #NephJC
Hyponatremia is one of the most common electrolyte disorders in hospitalized patients and is consistently linked to worse outcomes. Correcting sodium improves the numbers—but does it improve short-term clinical outcomes?
Check out Brian Rifkin VA and the new #NephJC format
NSMC intern, and Visual abstract maestro, Aakash Shingada shines again with a fantastic visual abstract.
For full resolution image, click here.
